Skip to main content
GutCited

Bacillus coagulans Figures

8 figures issues de recherches évaluées par des pairs

Tous Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 2
Figure 2 Chart

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3
Figure 3 Chart

Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3. Change in stool consistency from baseline (visit 2/d 1) to end of treatment (visit 4/d 80) in Test-G and Placebo-H. The Bristol stool form scale is used to assess the stool consistency as reported by total number of subjects.
Figure 4 Chart

Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 4. Clustering of multivariate data using principal component analysis analysis of responses for different variables of quality of life from Test-G (G) and Placebo-H (H) arms at end of treatment (visit 04). Variables considered are— abdominal pain,
Figure 5 Chart

Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 1. The flowchart of study protocol.
Figure 6 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 2. The effect of probiotic intervention on clinical improvement assessed by IBS-SSS scores (a–f). * indicates a statistically significant improvement (p < 0.05) between both the groups given probiotic intervention and the placebo group in the tot
Figure 7 Chart

Probiotic intervention outcomes assessed by IBS Severity Scoring System (IBS-SSS) in a three-arm clinical trial. Both Bifidobacterium lactis BI040 and Bacillus coagulans BC300 groups showed statistically significant improvement in total IBS-SSS scores compared to placebo.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 8
Figure 8 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 9
Figure 9 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …